The observation that anti-APL therapy reduced PML-RARα and enhanced PPARγ but could not normalize dyslipidemia in APL patients indicates that other important regulator(s) may participate in the regulation of lipid metabolism disorder in APL patients during induction therapy. Here, PPARG is linked to metabolic syndrome.